HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Shouhui Tech - The Business Outlook and Stock Price Performance Are Not Optimistic

China Healthcare Weekly (Jan.26)- Stocks Best Buying Point, Tragic PD-L1, Tiantan Biological Product

WuXi AppTec (2359.HK/603259.CH) - Behind the Plunge Is a War

WuXi XDC Cayman (2268.HK) - Would It Be An "Oasis in the Desert"?

Wuxi Biologics (2269.HK) - The Business Update Has Torn Away the Last Fig Leaf

WuXi AppTec (2359.HK/603259.CH) - How Bad Things Could Be?

Equity Bottom-Up

<ul>
<li>WuXi Bio’s optimism about new orders failed to generated expected surge in its stock price. Many investors raised great doubts about the credibility and professionalism in communication of WuXi Bio.</li>
<li>It’s easy/cost-effective for WuXi Bio to “adjust” order number. However, it’s more difficult to inflate revenue/cash flow. We have to wait for future financial results to know the real situation.</li>
<li>XBI is essentially “a bond”.Recent surge of XBI is driven by the expectations of Fed's rate cut + US soft landing, rather than virtual improvement of external environment.Much remains unclear.  </li>
</ul>


WuXi Bio’s optimism about new orders failed to generated expected surge in its stock price. Many investors raised great doubts about the credibility and professionalism in communication of WuXi Bio.
It’s easy/cost-effective for WuXi Bio to “adjust” order number. However, it’s more difficult to inflate revenue/cash flow. We have to wait for future financial results to know the real situation.
XBI is essentially “a bond”.Recent surge of XBI is driven by the expectations of Fed's rate cut + US soft landing, rather than virtual improvement of external environment.Much remains unclear.  


Wuxi Biologics (2269.HK) - Dramatic Changes in Management Forecasts Fail to Bring Back Confidence